文献速递冠心病心力衰竭与心肌病

血浆DPP3水平预测急性冠脉综合征患者心源性休克与死亡

Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究基于多中心SPUM-ACS队列(n=4787),检测ACS患者基线及12-24小时血浆cDPP3水平。结果显示cDPP3与院内CS独立相关(每log-2增加HR 1.38),并独立预测30天和1年死亡;持续升高者30天死亡风险增加13.4倍。

要点

  • cDPP3可独立预测ACS患者院内CS及30天、1年死亡。
  • 持续升高的cDPP3与30天死亡风险增加13.4倍相关。
  • cDPP3提供超出GRACE 2.0评分和ORBI风险评分的预后信息。

核心结论

  • cDPP3是ACS患者心源性休克和死亡的新型标志物,可改善早期风险评估。

研究设计与样本

  • 多中心前瞻性SPUM-ACS研究,纳入4787例ACS患者,检测基线及12-24小时血浆cDPP3水平。

主要发现

  • 结果在不同患者亚组中一致。

临床怎么用

  • 在ACS患者中可考虑检测血浆cDPP3以辅助早期识别心源性休克和死亡高风险者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS). METHODS: Plasma cDPP3 levels were assessed at baseline and 12-24 h after presentation in patients with ACS prospectively enrolled into the multi-centre SPUM-ACS study (n = 4787). RESULTS: Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score [per log-2 increase, hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.05-1.82, P = .021]. High cDPP3 was an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P < .001) and at one year (HR 1.61, 95% CI 1.28-2.02, P < .001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 h were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P < .001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P < .001). Results were consistent across various patient subgroups. CONCLUSIONS: This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Wenzl FA, Bruno F, Kraler S, et al. Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. Eur Heart J. 2023. PMID: 37632743. doi:10.1093/eurheartj/ehad545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。